ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 91

Type I IFN Production Is Induced By Non-Haematopoietic Tissue Cells but Not Plasmacytoid Dendritic Cells in Preclinical Autoimmunity and SLE

Antonios Psarras1,2,3, Adewonuola Alase1, Agne Antanaviciute4, Ian Carr4, Miriam Wittmann1,2, George C Tsokos5, Paul Emery1,6 and Edward M Vital1,2, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 3Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, MA, 4Leeds Institute for Data Analytics, University of Leeds, Leeds, United Kingdom, 5Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 6Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Autoimmunity, Interferons and systemic lupus erythematosus (SLE), Lupus

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Session Title: Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: SLE is characterized by persistently high type I IFN activity. Plasmacytoid dendritic cells (pDCs) produce large amounts of IFNs in viral infections in response to nucleic acids and they have therefore been postulated to be the main source of type I IFNs in SLE. However, the precise role of pDCs in autoimmunity still remains unclear. The aim of this study was to investigate the source of type I IFN in patients with established SLE and preclinical autoimmunity.

Methods: Patients with SLE meeting 2012 ACR/SLICC criteria and healthy donors were recruited alongside therapy-naïve individuals presenting with ANA and 1 clinical symptom (At-Risk). IFN activity was evaluated by a score of IFN-responsive genes in the peripheral blood using TaqMan. pDCs were immunophenotyped and studied in vitro for production of cytokines and induction of T cell responses using flow cytometry. pDCs were sorted and sequenced using high-sensitive RNA sequencing. IFN expression was visualised in skin biopsies using in situ hybridisation. Keratinocytes were isolated from fresh skin biopsies and cultured in vitro; IFN production was measured by qPCR and ELISA.

Results: Most of SLE and At-Risk patients had increased IFN activity, which correlated with disease activity. In contrast, circulating pDCs were decreased in both SLE and At-Risk patients and their numbers did not correlate with any clinical features or IFN status. In vitro stimulation with TLR9 or TLR7 agonists revealed that pDCs from SLE and At-Risk patients could not produce IFN-α and TNF-α. In addition, they induced significantly less T cell activation and proliferation compared to pDCs from healthy donors. RNA-seq data analysis showed an upregulation of IFN-responsive genes in most of the SLE and At-Risk pDCs as well as pathways related to immune regulation and senescence but not transcripts of any IFN subtypes. Phenotypically, SLE pDCs were characterised by increased telomeric erosion. In situ hybridization revealed high IFN expression in the epidermis but not in lymphocyte-infiltrating areas of lesional biopsies from SLE patients. High expression of IFN was also observed in epidermis of At-Risk individuals without any signs of cutaneous inflammation. In vitro stimulation of freshly isolated keratinocytes from these also showed a notable increase in IFN production.

Conclusion: In SLE, non-haematopoietic tissue resident cells are a dominant source of IFN and this is present prior to clinically overt disease. Meanwhile, the professional IFN-producing pDCs have lost their immunogenic properties. These findings suggest an important role for tissue resident cells in autoimmunity and may facilitate novel therapeutic interventions.


Disclosure: A. Psarras, None; A. Alase, None; A. Antanaviciute, None; I. Carr, None; M. Wittmann, Novartis, 5,Janssen, 5,AbbVie Inc., 5,Celgene Corporation, 5; G. C. Tsokos, Janssen, 5,Silicon Pharmaceuticals, 9,ABPRO, 9; P. Emery, Bristol-Myers Squibb, 2, 5,Pfizer, Inc., 2, 5,Roche, 2, 5,Novartis, 5,UCB, Inc., 5,Abbott, 2, 5,Merck & Co., 2; E. M. Vital, Roche, 2, 5,GlaxoSmithKline, 2, 5,AstraZeneca, 2, 5.

To cite this abstract in AMA style:

Psarras A, Alase A, Antanaviciute A, Carr I, Wittmann M, Tsokos GC, Emery P, Vital EM. Type I IFN Production Is Induced By Non-Haematopoietic Tissue Cells but Not Plasmacytoid Dendritic Cells in Preclinical Autoimmunity and SLE [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/type-i-ifn-production-is-induced-by-non-haematopoietic-tissue-cells-but-not-plasmacytoid-dendritic-cells-in-preclinical-autoimmunity-and-sle/. Accessed March 23, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/type-i-ifn-production-is-induced-by-non-haematopoietic-tissue-cells-but-not-plasmacytoid-dendritic-cells-in-preclinical-autoimmunity-and-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences